Dr. John Leonard Discusses New Treatments for Follicular Lymphoma

OncLive recently reported on a presentation made by Lymphoma Program Director, Dr. John Leonard at the 2016 International Congress on Hematologic Malignancies on novel treatments that could improve the long term survival of patients with follicular lymphoma. In introducing this topic he noted,

“Most patients will not die from follicular lymphoma, and that’s very reassuring. About 80% of patients will die with their follicular lymphoma and not of their follicular lymphoma…That really tells you something. If 80% of patients are not going to die from their disease, we can make a patient feel a lot better and can guide how we treat the patient.”

The article than summarizes Dr. Leonard’s discussion of these potential new treatments. Some of these treatments for follicular lymphoma are currently being investigated in clinical trials at Weill Cornell Medicine. If you are interested in a trial for follicular lymphoma, please look to our Joint Clinical Trials listings.

Dr. John Leonard Discusses How He Treats Mantle Cell Lymphoma

During the American Society of Hematology’s inaugural meeting on mantle cell lymphoma (MCL), Lymphoma Program Director, Dr. John Leonard discussed his treatment approach to patients with MCL. As TargetedOncology notes Dr. Leonard’s approach includes two key principles:

The first is to observe patients with asymptomatic MCL for as long as possible. In discussing the watch-and-wait approach, Leonard referred colleagues to data from the 2009 study that he co-authored in the Journal of Clinical Oncology, “Outcome of Deferred Initial Therapy in Mantle-Cell Lymphoma.”1 The overall survival (OS) of patients in the observation group exceeded that of patients in the early treatment group.

The second key principle that he suggested was to begin with less intensive initial treatments when needed due to their lower toxicity levels. “It’s true that less intensive treatments might have more chronic toxicity, but intensive treatments are unquestionably more toxic in the short term and can have longer-term toxicities as well,” he said.

You can read the rest of the article for a more in-depth summary of Dr. Leonard’s approach to treating patients with MCL.

REDLAMP – Review of Emerging Data for Lymphoma Patients – “Video Journal Club” Launched by Weill Cornell Lymphoma Program

Red Lamp logoThe Lymphoma Program at Weill Cornell Medical College, Meyer Cancer Center, and NewYork-Presbyterian is pleased to announce the initiation of a novel program to better inform patients and families dealing with lymphoma, chronic lymphocytic leukemia, and related disorders.

We will be presenting regular (roughly weekly) video programs where faculty briefly (3-5 minutes) review a new research publication that is important for lymphoma patients to learn about in terms that are understandable and relevant. The topics will be selected by our expert lymphoma faculty based on their importance to the field and our desire to make sure that lymphoma patients learn about new developments in a timely fashion.

The program will be named “REDLAMP” – Review of Emerging Data for Lymphoma Patients. Beyond the acronym, RED is also a nod to the colors of Weill Cornell Medical College, Cornell University and NewYork-Presbyterian (and blood cancers in general), while “LAMP” references our desire to “shine light” on important information for patients.

Our first video can be found below:

You can follow Lymphoma Program Director John Leonard @JohnPLeonardMD.

We encourage you to follow us on Twitter, Youtube, and Facebook where we will highlight new videos are about research publications as they are released. We also welcome your feedback, suggestions and questions about this project. If you have other questions about our lymphoma program or clinical trials or would like to see one of our lymphoma specialists, please contact us at 646-962-2074.